Wells Fargo Reiterates Overweight Rating on PTC Therapeutics, Inc. (PTCT)

Market Context

PTC Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $71.97 with a market capitalization of $6.1B. The stock has gained 45.1% over the past 52 weeks.

Analyst coverage from Wells Fargo provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for PTC Therapeutics, Inc.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for PTC Therapeutics, Inc.

Among the 10 most recent ratings: 8 Buy, 2 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Aug 13, 2026	Wells Fargo	Overweight	N/A
Jul 31, 2026	Morgan Stanley	Overweight	N/A
Jul 31, 2026	Wells Fargo	Overweight	N/A
Jul 20, 2026	Wells Fargo	Overweight	N/A
Jul 16, 2026	Cantor Fitzgerald	Overweight	N/A

Related Tools: Analyst Ratings Dashboard | View PTCT Stock Page